BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smeester BA, Slipek NJ, Pomeroy EJ, Laoharawee K, Osum SH, Larsson AT, Williams KB, Stratton N, Yamamoto K, Peterson JJ, Rathe SK, Mills LJ, Hudson WA, Crosby MR, Wang M, Rahrmann EP, Moriarity BS, Largaespada DA. PLX3397 treatment inhibits constitutive CSF1R-induced oncogenic ERK signaling, reduces tumor growth, and metastatic burden in osteosarcoma. Bone 2020;136:115353. [PMID: 32251854 DOI: 10.1016/j.bone.2020.115353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu J, Yao Q, Peng Y, Dong Z, Tang L, Su X, Liu L, Chen C, Ramalingam M, Cheng L. Identification of Small-Molecule Inhibitors for Osteosarcoma Targeted Therapy: Synchronizing In Silico, In Vitro, and In Vivo Analyses. Front Bioeng Biotechnol 2022;10:921107. [DOI: 10.3389/fbioe.2022.921107] [Reference Citation Analysis]
2 Vaynrub A, Healey JH, Tap W, Vaynrub M. Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations. Onco Targets Ther 2022;15:53-66. [PMID: 35046667 DOI: 10.2147/OTT.S345878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Han G, Guo Q, Li N, Bi W, Xu M, Jia J. Screening and Analysis of Biomarkers in the miRNA-mRNA Regulatory Network of Osteosarcoma. J Healthc Eng 2022;2022:8055052. [PMID: 35340229 DOI: 10.1155/2022/8055052] [Reference Citation Analysis]
4 Li J, Shi H, Yuan Z, Wu Z, Li H, Liu Y, Lu M, Lu M. The role of SPI1-TYROBP-FCER1G network in oncogenesis and prognosis of osteosarcoma, and its association with immune infiltration. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09216-w] [Reference Citation Analysis]
5 Wu NF, Yamamoto J, Bouvet M, Hoffman RM. A Novel Procedure for Orthotopic Tibia Implantation for Establishment of a More Clinical Osteosarcoma PDOX Mouse Model. In Vivo 2021;35:105-9. [PMID: 33402455 DOI: 10.21873/invivo.12237] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Li J, Su L, Xiao X, Wu F, Du G, Guo X, Kong F, Yao J, Zhu H. Development and Validation of Novel Prognostic Models for Immune-Related Genes in Osteosarcoma. Front Mol Biosci 2022;9:828886. [DOI: 10.3389/fmolb.2022.828886] [Reference Citation Analysis]
7 Beck J, Ren L, Huang S, Berger E, Bardales K, Mannheimer J, Mazcko C, LeBlanc A. Canine and murine models of osteosarcoma. Vet Pathol 2022;:3009858221083038. [PMID: 35341404 DOI: 10.1177/03009858221083038] [Reference Citation Analysis]
8 Torres HM, VanCleave AM, Vollmer M, Callahan DL, Smithback A, Conn JM, Rodezno-Antunes T, Gao Z, Cao Y, Afeworki Y, Tao J. Selective Targeting of Class I Histone Deacetylases in a Model of Human Osteosarcoma. Cancers (Basel) 2021;13:4199. [PMID: 34439353 DOI: 10.3390/cancers13164199] [Reference Citation Analysis]